Type 1 diabetes mellitus abrogates compensatory augmentation of myocardial neuregulin-1β/ErbB in response to myocardial infarction resulting in worsening heart failure

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Odiete, Oghenerukevwe ^a   Konik, Ewa A ^a   Sawyer, Douglas B ^a   Hill, Michael F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ErbB2; ErbB4; Heart failure; MDM2; Myocardial infarction; Neuregulin 1; Type 1 diabetes mellitus

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; NEU DIFFERENTIATION FACTOR; NEUREGULIN 1 BETA; PROTEIN MDM2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECEPTOR UPREGULATION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; HEART FAILURE; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NEUREGULIN-1; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2;

EID: 84875288392     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-52     Document Type: Article

References (44)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
2. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996, 28:1661-1669. 10.1016/S0735-1097(96)00397-X, 8962549.
3. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989, 14:49-57. 10.1016/0735-1097(89)90053-3, 2661630.
4. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995, 378:390-394. 10.1038/378390a0, 7477376.
5. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378:394-398. 10.1038/378394a0, 7477377.
6. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J, Chien KR, Lee KF. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465. 10.1038/nm0502-459, 11984589.
7. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998, 273:10261-10269. 10.1074/jbc.273.17.10261, 9553078.
8. Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA, Kelly RA, Sawyer DB. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 2003, 35:1473-1479. 10.1016/j.yjmcc.2003.09.012, 14654373.
9. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hübner N, Chien KR, Birchmeier C, Garratt AN. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 2002, 99:8880-8885. 10.1073/pnas.122249299, 124392, 12072561.
10. Hedhli N, Huang Q, Kalinowski A, Palmeri M, Hu X, Russell RR, Russell KS. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation 2011, 123:2254-2262. 10.1161/CIRCULATIONAHA.110.991125, 3104502, 21555713.
11. Gui C, Zhu L, Hu M, Lei L, Long Q. Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy. Cardiovasc Pathol 2012, 21:414-420. 10.1016/j.carpath.2011.12.006, 22285193.
12. Li B, Zheng Z, Wei Y, Wang M, Peng J, Kang T, Huang X, Xiao J, Li Y, Li Z. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol 2011, 10:69. 10.1186/1475-2840-10-69, 3170868, 21798071.
13. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46:760-765. 10.1007/s00125-003-1116-6, 12774166.
14. Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011, 378:140-146. 10.1016/S0140-6736(11)60471-6, 21705065.
15. Retnakaran R, Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet 2008, 371:1790-1799. 10.1016/S0140-6736(08)60767-9, 18502304.
16. Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, Hill MF. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol 2007, 42:884-895. 10.1016/j.yjmcc.2006.12.018, 2677446, 17320100.
17. Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, Moye L, Braunwald E, Pfeffer MA. Survival And Ventricular Enlargement (SAVE) Investigators: ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 2002, 106:1251-1255. 10.1161/01.CIR.0000032313.82552.E3, 12208801.
18. Kuramochi Y, Lim CC, Guo X, Colucci WS, Liao R, Sawyer DB. Myocyte contractile activity modulates norepinephrine cytotoxicity and survival effects of neuregulin-1beta. Am J Physiol Cell Physiol 2004, 286:C222-C229. 10.1152/ajpcell.00312.2003, 14522821.
19. Rohrbach S, Niemann B, Silber RE, Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium - depressed expression and attenuated activation. Basic Res Cardiol 2005, 100:240-249. 10.1007/s00395-005-0514-4, 15685397.
20. Peng X, Guo X, Borkan SC, Bharti A, Kuramochi Y, Calderwood S, Sawyer DB. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J Biol Chem 2005, 280:13148-13152.
21. Lemmens K, Segers VF, Demolder M, De Keulenaer GW. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 2006, 281:19469-19477. 10.1074/jbc.M600399200, 16698793.
22. Mytas DZ, Stougiannos PN, Zairis MN, Foussas SG, Pyrgakis VN, Kyriazis IA. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J Diabetes Complications 2009, 23:273-282. 10.1016/j.jdiacomp.2007.12.005, 18413201.
23. Icli B, Bharti A, Pentassuglia L, Peng X, Sawyer DB. ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response. Biochem Biophys Res Commun 2012, 418:116-121. 10.1016/j.bbrc.2011.12.144, 3273580, 22244893.
24. Marti U, Hug M. Acinar and cellular distribution and mRNA expression of the epidermal growth factor receptor are changed during liver regeneration. J Hepatol 1995, 23:318-327.
25. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001, 3:973-982. 10.1038/ncb1101-973, 11715018.
26. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Anversa P, Kajstura J. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 2001, 50:2363-2375. 10.2337/diabetes.50.10.2363, 11574421.
27. Nakamura H, Matoba S, Iwai-Kanai E, Kimata M, Hoshino A, Nakaoka M, Katamura M, Okawa Y, Ariyoshi M, Mita Y, Ikeda K, Okigaki M, Adachi S, Tanaka H, Takamatsu T, Matsubara H. p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation. Circ Heart Fail 2012, 5:106-115. 10.1161/CIRCHEARTFAILURE.111.961565, 22075967.
28. Rota M, LeCapitaine N, Hosoda T, Boni A, De Angelis A, Padin-Iruegas ME, Esposito G, Vitale S, Urbanek K, Casarsa C, Giorgio M, Lüscher TF, Pelicci PG, Anversa P, Leri A, Kajstura J. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res 2006, 99:42-52. 10.1161/01.RES.0000231289.63468.08, 16763167.
29. Miller TA, Icli B, Cote GM, Lebrasseur NK, Borkan SC, Pimentel DR, Peng X, Sawyer DB. Palmitate alters neuregulin signaling and biology in cardiac myocytes. Biochem Biophys Res Commun 2009, 379:32-37. 10.1016/j.bbrc.2008.11.150, 2654183, 19070592.
30. Kosugi R, Shioi T, Watanabe-Maeda K, Yoshida Y, Takahashi K, Machida Y, Izumi T. Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. Circ J 2006, 70:482-488. 10.1253/circj.70.482, 16565569.
31. Bilim O, Takeishi Y, Kitahara T, Arimoto T, Niizeki T, Sasaki T, Goto K, Kubota I. Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus. Cardiovasc Diabetol 2008, 7:2. 10.1186/1475-2840-7-2, 2265681, 18241357.
32. Hamblin M, Smith HM, Hill MF. Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione. J Card Fail 2007, 13:884-892. 10.1016/j.cardfail.2007.07.002, 2685187, 18068623.
33. Maeda CY, Fernandes TG, Timm HB, Irigoyen MC. Autonomic dysfunction in short-term experimental diabetes. Hypertension 1995, 26:1100-1104. 10.1161/01.HYP.26.6.1100, 7498976.
34. Hicks KK, Seifen E, Stimers JR, Kennedy RH. Effects of streptozotocin-induced diabetes on heart rate, blood pressure and cardiac autonomic nervous control. J Auton Nerv Syst 1998, 69:21-30. 10.1016/S0165-1838(98)00004-6, 9672120.
35. Sakamoto J, Barr RL, Kavanagh KM, Lopaschuk GD. Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am J Physiol Heart Circ Physiol 2000, 278:H1196-H1204.
36. Nagareddy PR, Xia Z, MacLeod KM, McNeill JH. N-acetylcysteine prevents nitrosative stress-associated depression of blood pressure and heart rate in streptozotocin diabetic rats. J Cardiovasc Pharmacol 2006, 47:513-520. 10.1097/01.fjc.0000211744.93701.25, 16680064.
37. Borges GR, de Oliveira M, Salgado HC, Fazan R. Myocardial performance in conscious streptozotocin diabetic rats. Cardiovasc Diabetol 2006, 5:26. 10.1186/1475-2840-5-26, 1698470, 17144912.
38. Banyasz T, Kalapos I, Kelemen SZ, Kovacs T. Changes in cardiac contractility in IDDM and NIDDM diabetic rats. Gen Physiol Biophys 1996, 15:357-369.
39. Banyasz T, Kovacs T. Altered [3H]ouabain binding to cardiac muscle in insulin dependent and non-insulin-dependent diabetic rats. Exp Physiol 1998, 83:65-76.
40. Adolphe AB, Glasofer ED, Troetel WM, Weiss AJ, Manthei RW. Preliminary pharmacokinetics of streptozotocin, an antineoplastic antibiotic. J Clin Pharmacol 1977, 17:379-388. 10.1002/j.1552-4604.1977.tb04620.x, 142097.
41. Fein FS, Strobeck JE, Malhotra A, Scheuer J, Sonnenblick EH. Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 1981, 49:1251-1261. 10.1161/01.RES.49.6.1251, 7030513.
42. Pierce GN, Kutryk MJ, Dhalla NS. Alterations in Ca2+ binding by and composition of the cardiac sarcolemmal membrane in chronic diabetes. Proc Natl Acad Sci USA 1983, 80:5412-5416. 10.1073/pnas.80.17.5412, 384266, 6577435.
43. Kalinowski A, Plowes NJ, Huang Q, Berdejo-Izquierdo C, Russell RR, Russell KS. Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB J 2010, 24:2567-2575. 10.1096/fj.08-129072, 2887255, 20215529.
44. Debelec-Butuner B, Alapinar C, Varisli L, Erbaykent-Tepedelen B, Hamid SM, Gonen-Korkmaz C, Korkmaz KS. Inflammation-mediated abrogation of androgen signaling: An in vitro model of prostate cell inflammation. Mol Carcinog in press.